Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study

Haemophilia

Volumn 22, Issue 4, 2016, Pages 537-542

  Morfini, M ^a   Dragani, A ^b   Paladino, E ^c   Radossi, P ^d   Di Minno, G ^e   Mazzucconi, M G ^f   Rossetti, G ^g   Barillari, G ^h   Napolitano, M ⁱ   Tagariello, G ^d  

^a Italian Association of Haemophilia Centres (AICE)   (Italy)

^b Regional Hospital   (Italy)

^c University Hospital of Florence   (Italy)

^d Regional Hospital   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PALERMO   (Italy)

Author keywords

DNA Recombinant proteins; factor IX; genotype; haemophilia B; pharmacokinetics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATIONAL STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; GENOTYPE; HEMOPHILIA B; HUMAN; ITALY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MISSENSE MUTATION; MULTICENTER STUDY; NONSENSE MUTATION; PRIORITY JOURNAL; SAMPLING; SAMPLING TIME; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION;

EID: 84978998418     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12916     Document Type: Article

References (22)

1. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261–5.
2. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190–7.
3. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600–6.
4. White GC 2nd, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35(Suppl. 2): 33–8.
5. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133–9.
6. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233–43 Erratum in: Haemophilia 2007; 13: 450.
7. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384–6.
8. Lee M, Morfini M, Schulman S, Ingerslev J and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Available at: https://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf?hhSearchTerms=%22morfini%22. Accessed January 2, 2016.
9. Belvini D, Salviato R, Radossi P et al., AICE HB Study Group. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005; 90: 635–42.
10. Prowse CV. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1191–6.
11. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20: 398–406.
12. Andreeva T, Zorenko VY, Davydkin I et al. Safety and efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic treatment in patients with severe and moderate Hemophilia B. Blood 2015, 126, Abstract n. 3532.
13. Alamelu J, Bevan D, Sorensen B, Rangarajan S. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with haemophilia B: a prospective crossover study. J Thromb Haemost 2014; 12: 2044–8.
14. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695–701.
15. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–11.
16. Martinowitz U, Shapiro A, Quon DV et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia 2012; 18: 881–7.
17. ®) in patients with severe haemophilia B. Haemophilia 2013; 19: 674–8.
18. Aznar JA, Cabrera N, Matysiak M et al. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Haemophilia 2009; 15: 1243–8.
19. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666–72.
20. Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thromb Res 1986; 42: 471–6.
21. Longo G, Cinotti S, Filimberti E et al. Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. Eur J Haematol 1987; 39: 426–33.
22. Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305–12.